Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Clinical reporting for Emory Healthcare

Share this on social media:

GenomOncology today announced that Emory Healthcare is now using the company’s GO Pathology Workbench system as part of its clinical reporting process, enabling the return of clinical reports to ordering physicians more rapidly and in a comprehensive format that aids their decision making.

‘Today's Molecular Pathology lab is challenged by an overwhelming amount of information that is dispersed among siloed databases and tools. This makes the interpretation of molecular data onerous for pathologists and oncologists. Our goal is to enable precision oncology by connecting disparate tools and databases and allowing data to flow end to end to aid the case workflow. The GO Pathology Workbench provides reporting that is comprehensive and actionable, thus supports decision making by oncologists,’ added Manuel Glynias, Founder and CEO of GenomOncology.

The GO Pathology Workbench utilizes the GO Knowledge Management System (GO KMS) that leverages the work of Vanderbilt University's My Cancer Genome team, led by Dr Mia Levy. The GO KMS can match a patient's biomarkers to therapies, prognoses and Clinical Trials. This capability means that the new Emory report highlights only the relevant therapies and clinical trials.

‘GenomOncology's Pathology Workbench is an important part of our solid tumour panel clinical reporting workflow, and we're also planning on using it for our new myeloid panel,’ said Charles Hill, MD, PhD, director of the Molecular Diagnostics Laboratory at Emory University Hospital. ‘In addition, we are benefiting from GenomOncology's engaged biotechnology partnership.’